Therefore, the combination of traditional CSF biomarkers (e.g., Aβ1–42/Aβ1–40 ratio, t-tau/Aβ1–42, and p-tau/Aβ1–42 ratios) may improve the diagnostic accuracy of cognitive decline in LD patients. The gene discussed is MAPT; the disease is Mental deterioration.